AR111651A1 - Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación - Google Patents
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinaciónInfo
- Publication number
- AR111651A1 AR111651A1 ARP180101056A ARP180101056A AR111651A1 AR 111651 A1 AR111651 A1 AR 111651A1 AR P180101056 A ARP180101056 A AR P180101056A AR P180101056 A ARP180101056 A AR P180101056A AR 111651 A1 AR111651 A1 AR 111651A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugates
- antibodies
- combination therapies
- type receiver
- include toll
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll. Uso de tales conjugados para el tratamiento del cáncer. Los conjugados comprenden anticuerpos anti-HER2. Los conjugados se usan en combinación con un segundo agente terapéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762491425P | 2017-04-28 | 2017-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR111651A1 true AR111651A1 (es) | 2019-08-07 |
Family
ID=62244515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101056A AR111651A1 (es) | 2017-04-28 | 2018-04-25 | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200164084A1 (es) |
EP (1) | EP3615033A1 (es) |
JP (1) | JP2020517724A (es) |
KR (1) | KR20190140472A (es) |
CN (1) | CN110678183A (es) |
AR (1) | AR111651A1 (es) |
AU (1) | AU2018260505A1 (es) |
BR (1) | BR112019022495A2 (es) |
CA (1) | CA3059466A1 (es) |
CL (1) | CL2019003050A1 (es) |
MX (1) | MX2019012811A (es) |
RU (1) | RU2019138337A (es) |
TW (1) | TW201841661A (es) |
WO (1) | WO2018198091A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
JP7011764B2 (ja) | 2016-07-07 | 2022-01-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 抗体アジュバント複合体 |
JP2019537438A (ja) | 2016-11-01 | 2019-12-26 | アナプティスバイオ インコーポレイティッド | Tim−3(t細胞イムノグロブリンおよびムチンタンパク質3)に対する抗体 |
AU2018205401A1 (en) * | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
JP7386536B2 (ja) | 2017-08-22 | 2023-11-27 | ダイナヴァックス テクノロジーズ コーポレイション | アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用 |
WO2019099412A1 (en) | 2017-11-14 | 2019-05-23 | Dynavax Technologies Corporation | Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof |
WO2020056008A1 (en) | 2018-09-12 | 2020-03-19 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
US20220226491A1 (en) * | 2019-03-15 | 2022-07-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates Targeting PD-L1 |
AU2020241686A1 (en) * | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
US20220242871A1 (en) * | 2019-06-10 | 2022-08-04 | Sutro Biopharma, Inc. | 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF |
BR112021025699A2 (pt) | 2019-06-19 | 2022-03-03 | Silverback Therapeutics Inc | Anticorpos anti-mesotelina e imunoconjugados dos mesmos |
CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
WO2022006327A1 (en) | 2020-07-01 | 2022-01-06 | Silverback Therapeutics, Inc. | Anti-asgr1 antibody conjugates and uses thereof |
CN116056725A (zh) * | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
CN117279664A (zh) | 2021-04-10 | 2023-12-22 | 普方生物制药美国公司 | Folr1结合剂、其偶联物及其使用方法 |
CA3216459A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
WO2023044483A2 (en) * | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2024051747A1 (en) * | 2022-09-06 | 2024-03-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | A pharmaceutical composition of anti-her2 antibody-immune agonist conjugate and applications thereof |
Family Cites Families (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
DE69232706T2 (de) | 1991-05-01 | 2002-11-28 | Jackson H M Found Military Med | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
DK0885002T3 (da) | 1996-03-04 | 2011-08-22 | Penn State Res Found | Materialer og fremgangsmåder til forøgelse af cellulær internalisering |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
EP0954282B1 (en) | 1997-01-16 | 2005-01-19 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP2180007B2 (en) | 1998-04-20 | 2017-08-30 | Roche Glycart AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
HUP0104693A3 (en) | 1998-12-16 | 2003-12-29 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
EP2264166B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
EE05450B1 (et) | 2000-07-19 | 2011-08-15 | Warner-Lambert Company | 4-jodofenlaminobenshdroksaamhapete oksgeenitud estrid, nende kristallvormid ja farmatseutilised kompositsioonid ning kasutamine |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
AU2002357060A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
PL221491B1 (pl) | 2002-03-08 | 2016-04-29 | Eisai R&D Man Co | Związki makrocykliczne, środek farmaceutyczny zawierający te związki oraz zastosowanie tych związków |
US20040248151A1 (en) | 2002-04-05 | 2004-12-09 | Ventana Medical Systems, Inc. | Method for predicting the response to HER2-directed therapy |
ES2401428T3 (es) | 2002-04-10 | 2013-04-19 | Genentech, Inc. | Variantes de anticuerpos anti-HER2 |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
SI2206517T1 (sl) | 2002-07-03 | 2023-12-29 | Ono Pharmaceutical Co., Ltd. | Imunopotencirni sestavki,ki obsegajo protitelesa proti PD-L1 |
GB0215823D0 (en) | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
ES2318167T3 (es) | 2002-07-15 | 2009-05-01 | The Trustees Of Princeton University | Compuestos de union a iap. |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Pd−1に対する抗体およびその使用 |
EP2368578A1 (en) | 2003-01-09 | 2011-09-28 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
JP2007523061A (ja) | 2004-01-16 | 2007-08-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Smacペプチドミメティクスおよびその使用法 |
MXPA06008095A (es) | 2004-01-16 | 2007-03-28 | Univ Michigan | Mimeticos de smac conformacionalmente restringidos y sus usos. |
EP1740173A4 (en) | 2004-03-23 | 2009-05-27 | Genentech Inc | AZABICYCLOOCTAN IAP INHIBITORS |
EP2253614B1 (en) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
ES2524449T3 (es) | 2004-07-02 | 2014-12-09 | Genentech, Inc. | Inhibidores de IAP |
WO2006010118A2 (en) | 2004-07-09 | 2006-01-26 | The Regents Of The University Of Michigan | Conformationally constrained smac mimetics and the uses thereof |
MX2007000490A (es) | 2004-07-12 | 2007-06-11 | Idun Pharmaceuticals Inc | Analogos de tetrapeptido. |
EP1773766B1 (en) | 2004-07-15 | 2014-04-02 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
BRPI0513681A (pt) | 2004-07-22 | 2008-05-13 | Genentech Inc | composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
CN101146803A (zh) | 2004-12-20 | 2008-03-19 | 健泰科生物技术公司 | Iap的吡咯烷抑制剂 |
PT1866339E (pt) | 2005-03-25 | 2013-09-03 | Gitr Inc | Moléculas de ligação a gitr e suas utilizações |
KR101339628B1 (ko) | 2005-05-09 | 2013-12-09 | 메다렉스, 인코포레이티드 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
NZ564592A (en) | 2005-07-01 | 2011-11-25 | Medarex Inc | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
WO2007004606A1 (ja) | 2005-07-04 | 2007-01-11 | Nikon Vision Co., Ltd. | 測距装置 |
CA2618218C (en) | 2005-07-21 | 2015-06-30 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
PT2573114T (pt) | 2005-08-10 | 2016-07-13 | Macrogenics Inc | Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos |
AU2006330051B2 (en) * | 2005-12-16 | 2011-08-18 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
NZ596494A (en) | 2006-01-13 | 2013-07-26 | Us Gov Nat Inst Health | Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells |
US20090136522A1 (en) * | 2006-03-24 | 2009-05-28 | Haynes Barton F | Multivalent Immunogen |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
NZ598890A (en) | 2007-04-30 | 2013-10-25 | Genentech Inc | Inhibitors of iap |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP2160401B1 (en) | 2007-05-11 | 2014-09-24 | Altor BioScience Corporation | Fusion molecules and il-15 variants |
CA2691089A1 (en) * | 2007-06-15 | 2008-12-24 | Immurx, Inc. | Use of tlr agonists and/or type 1 interferons to alleviate toxicity of tnf-r agonist therapeutic regimens |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
KR101584823B1 (ko) | 2007-09-12 | 2016-01-22 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 저해제 화합물과 화학치료제의 배합물 및 이의 사용방법 |
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
MX2010005783A (es) | 2007-11-27 | 2010-08-10 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas. |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
CA2720368C (en) | 2008-04-02 | 2017-08-22 | Macrogenics, Inc. | Her2/neu-specific antibodies and methods of using same |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
JP2012501670A (ja) | 2008-09-12 | 2012-01-26 | アイシス・イノベーション・リミテッド | Pd−1特異抗体およびその使用 |
MX2011003195A (es) | 2008-09-26 | 2011-08-12 | Dana Farber Cancer Inst Inc | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
CN104479018B (zh) | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
RU2012101999A (ru) | 2009-06-22 | 2013-07-27 | МЕДИММЬЮН, ЭлЭлСи | РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ |
IN2015DN02826A (es) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
JP5898082B2 (ja) | 2009-10-07 | 2016-04-06 | マクロジェニクス,インコーポレーテッド | フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法 |
EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
KR101573109B1 (ko) | 2009-11-24 | 2015-12-01 | 메디뮨 리미티드 | B7―h1에 대한 표적화된 결합 물질 |
ES2527143T3 (es) | 2009-12-07 | 2015-01-20 | Fundació Privada Institució Catalana De Recerca I Estudis Avançants | Anticuerpos frente a variante truncada CTF-611 de HER2 |
EP2513148B1 (en) | 2009-12-16 | 2016-08-31 | AbbVie Biotherapeutics Inc. | Anti-her2 antibodies and their uses |
CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
US8609095B2 (en) | 2010-03-04 | 2013-12-17 | Symphogen A/S | Anti-HER2 antibodies and compositions |
WO2011110604A1 (en) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Pd-1 antibody |
EP2558501B1 (en) | 2010-04-15 | 2016-09-07 | Alper Biotech, Llc | Monoclonal antibodies against her2 antigens, and uses therefor |
CN103118682A (zh) * | 2010-04-30 | 2013-05-22 | 加利福尼亚大学校务委员会 | 合成tlr7激动剂的磷脂缀合物的用途 |
HUE040213T2 (hu) | 2010-06-11 | 2019-02-28 | Kyowa Hakko Kirin Co Ltd | Anti-TIM antitest |
CA2802344C (en) | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
TW201247706A (en) * | 2011-03-08 | 2012-12-01 | Baylor Res Inst | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
RU2625034C2 (ru) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Антитела и другие молекулы, которые связывают в7-н1 и pd-1 |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
HUE051954T2 (hu) | 2011-11-28 | 2021-03-29 | Merck Patent Gmbh | ANTI-PD-L1 ellenanyagok és alkalmazásaik |
WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | ANTIGEN BINDING PROTEINS THAT BIND PD-L1 |
US20150104468A1 (en) | 2012-06-04 | 2015-04-16 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
LT2872171T (lt) | 2012-07-13 | 2021-04-26 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo reguliavimas |
US9845356B2 (en) | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
CN107892719B (zh) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
AU2013334610B2 (en) | 2012-10-24 | 2018-09-13 | Novartis Ag | IL-15R alpha forms, cells expressing IL-15R alpha forms, and therapeutic uses of IL-15R alpha and IL-15/IL-15R alpha complexes |
AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
MX2015010146A (es) | 2013-02-08 | 2016-05-31 | Novartis Ag | Sitios especificos para modificar anticuerpos para hacer inmunoconjugados. |
ME03796B (me) | 2013-03-15 | 2021-04-20 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
US9815897B2 (en) | 2013-05-02 | 2017-11-14 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
MY175308A (en) | 2013-05-18 | 2020-06-18 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
CN111423511B (zh) | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
KR102100419B1 (ko) | 2013-09-13 | 2020-04-14 | 베이진 스위찰랜드 게엠베하 | 항-pd1 항체 및 이의 치료 및 진단 용도 |
WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
WO2015081158A1 (en) | 2013-11-26 | 2015-06-04 | Bristol-Myers Squibb Company | Method of treating hiv by disrupting pd-1/pd-l1 signaling |
KR20160088429A (ko) | 2013-11-26 | 2016-07-25 | 노파르티스 아게 | 케톤-변형된 폴리펩티드에 대한 옥심 접합을 위한 방법 |
MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
JP2017509319A (ja) | 2014-01-15 | 2017-04-06 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | 免疫調節剤 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
EP3988572A1 (en) | 2014-01-28 | 2022-04-27 | Bristol-Myers Squibb Company | Anti-lag-3 antibodies to treat hematological malignancies |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
MX2016011627A (es) | 2014-03-12 | 2016-11-29 | Novartis Ag | Sitios especificos para modificar anticuerpos con el fin de hacer inmunoconjugados. |
TWI697500B (zh) | 2014-03-14 | 2020-07-01 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
SG11201608299TA (en) * | 2014-05-01 | 2016-11-29 | Novartis Ag | Compounds and compositions as toll-like receptor 7 agonists |
DK3148579T3 (da) | 2014-05-28 | 2021-03-08 | Agenus Inc | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf |
AU2015265870B2 (en) | 2014-05-29 | 2020-07-09 | Ventana Medical Systems, Inc. | PD-L1 antibodies and uses thereof |
KR101923326B1 (ko) | 2014-06-06 | 2018-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 |
WO2015195163A1 (en) | 2014-06-20 | 2015-12-23 | R-Pharm Overseas, Inc. | Pd-l1 antagonist fully human antibody |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
US10786578B2 (en) * | 2014-08-05 | 2020-09-29 | Novartis Ag | CKIT antibody drug conjugates |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
PE20170935A1 (es) * | 2014-09-12 | 2017-07-13 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados |
US10463732B2 (en) | 2014-10-03 | 2019-11-05 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
CN114920840A (zh) | 2014-10-14 | 2022-08-19 | 诺华股份有限公司 | 针对pd-l1的抗体分子及其用途 |
HUE047784T2 (hu) | 2014-11-06 | 2020-05-28 | Hoffmann La Roche | Anti-TIM3 antitestek és alkalmazási eljárások |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
CA2978892A1 (en) | 2015-03-06 | 2016-09-15 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind tim3 |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
MX2017015260A (es) | 2015-06-03 | 2018-02-19 | Squibb Bristol Myers Co | Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer. |
KR20180031728A (ko) | 2015-07-23 | 2018-03-28 | 인히브릭스 엘피 | 다가 및 다중특이적 gitr 결합 융합 단백질 |
EP3334758A1 (en) | 2015-08-12 | 2018-06-20 | Medimmune Limited | Gitrl fusion proteins and uses thereof |
MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
-
2018
- 2018-04-25 AR ARP180101056A patent/AR111651A1/es unknown
- 2018-04-26 TW TW107114319A patent/TW201841661A/zh unknown
- 2018-04-27 JP JP2019558622A patent/JP2020517724A/ja active Pending
- 2018-04-27 RU RU2019138337A patent/RU2019138337A/ru unknown
- 2018-04-27 US US16/608,608 patent/US20200164084A1/en not_active Abandoned
- 2018-04-27 KR KR1020197034693A patent/KR20190140472A/ko unknown
- 2018-04-27 CA CA3059466A patent/CA3059466A1/en not_active Abandoned
- 2018-04-27 WO PCT/IB2018/052948 patent/WO2018198091A1/en active Application Filing
- 2018-04-27 BR BR112019022495-5A patent/BR112019022495A2/pt not_active Application Discontinuation
- 2018-04-27 MX MX2019012811A patent/MX2019012811A/es unknown
- 2018-04-27 CN CN201880034958.9A patent/CN110678183A/zh active Pending
- 2018-04-27 EP EP18727050.9A patent/EP3615033A1/en not_active Withdrawn
- 2018-04-27 AU AU2018260505A patent/AU2018260505A1/en not_active Abandoned
-
2019
- 2019-10-24 CL CL2019003050A patent/CL2019003050A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN110678183A (zh) | 2020-01-10 |
RU2019138337A (ru) | 2021-05-31 |
JP2020517724A (ja) | 2020-06-18 |
US20200164084A1 (en) | 2020-05-28 |
BR112019022495A2 (pt) | 2020-06-16 |
CL2019003050A1 (es) | 2020-02-07 |
AU2018260505A1 (en) | 2019-10-31 |
MX2019012811A (es) | 2020-01-14 |
WO2018198091A1 (en) | 2018-11-01 |
KR20190140472A (ko) | 2019-12-19 |
TW201841661A (zh) | 2018-12-01 |
EP3615033A1 (en) | 2020-03-04 |
CA3059466A1 (en) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR111651A1 (es) | Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación | |
ECSP18038868A (es) | Conjugados de anticuerpo que comprenden un agonista del receptor tipo toll | |
ECSP19072235A (es) | Anticuerpos anti-ILT4 y fragmentos de unión a antígeno | |
AR113224A1 (es) | Conjugados de anticuerpo que comprenden un agonista de sting | |
CO2018001624A2 (es) | Conjugados anticuerpo anti-dll3-fármaco y métodos de uso | |
UY38236A (es) | COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3 | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
CL2017001217A1 (es) | Conjugados de droga de anticuerpos. | |
CL2017001916A1 (es) | Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso (divisional solicitud 468-2016) | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
ECSP17027870A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
BR112016030740A2 (pt) | diacorpos heterodiméricos biespecíficos e seus usos | |
CL2019001324A1 (es) | Anticuerpos anti-met, moleculas de unión a antígeno bispecificas que se unen a met y métodos de uso de los mismos. | |
ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
UY37456A (es) | Inmunoglobulinas y sus usos | |
AR120147A1 (es) | Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco | |
CL2018002050A1 (es) | Conjugados anticuerpo-fármaco dirigidos a gcc. | |
CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso | |
ECSP20082970A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
AR110942A1 (es) | Composiciones y métodos para terapias de células t con car | |
AR108690A1 (es) | Anticuerpos contra el miembro 21 de la superfamilia del receptor del factor de necrosis tumoral (anti-tnfrsf21) y métodos de uso de los mismos | |
EA201991330A1 (ru) | Способы лечения рака с помощью антител к tim-3 | |
AR105945A1 (es) | Composiciones y métodos usados para aumentar la respuesta inmune y terapia del cáncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |